Primena antipsihotika na teritoriji Soluna, Grčka
Sažetak
Uvod/Cilj. Tokom ekonomske krize u Grčkoj, zdravstvene vlasti su, u cilju smanjenja troškova u zdravstvenoj delatnosti, stimulisali propisivanje i korišćenje generičkih oblika lekova. Cilj istraživanja je bio analiza potrošnje generičkih lekova 12 grupa antipsihotika na osnovu njihovog prometa u apotekama u Solunu, drugog po veličini grada u Grčkoj. Metode. Uzorak prodatih registrovanih antipsihotika formiran je na osnovu elektronskog zdravstvenog kartona, koji je u primeni tokom poslednjih nekoliko godina u apotekama Grčke. Uzorak se odnosio na vanbolničku potrošnju lekova na teritoriji Soluna tokom perioda jul 2014-jun 2015. godine, a ne i na primenu lekova u bolničkim uslovima. Analizirani su originalni i generički oblici antipsihotika koji su bili registrovani u Grčkoj. Izračunata je zastupljenost generičkih oblika lekova u primeni. Obim prometa lekova procenjivan je putem definisane dnevne doze (DDDs) referentnog oblika leka (originalni lekovi i njihovi generični oblici). Rezultati. Od ukupnog prometa antipsihotika olanzapin je bio zastupljen sa 25%, kvetiapin sa 19%, haloperidol sa 19% i risperidon sa 14%. Procenat prodaje drugih antipsihotika iznosio je: amisulpirid - 7%, aripiprazol - 6%, ziprasidon - 4% i klozapin - 3%. Upotreba generičkih oblika lekova iznosila je 41% od ukupne prodaje antipsihotika (10,884 od 26,433 DDDs). Kada su u pitanju antipsihotici druge generacije, generički oblici lekova su korišćeni u visokom procentu u slučaju amisulpirida, olanzapina, risperidona i kvetiapina. Zaključak. Na ispitivanom uzorku, prodaja antipsihotika druge generacije iznosila je 78% od vanbolničke potorošnje antipsihotika na teritoriji Soluna. Potrošnja haloperidola je bila takođe značajna. Razmatrajući grčku praksu, procenat prodaje generičkih oblika lekova iz grupe antipsihotika je bio veoma veliki, čak i za neke novije antipsihotike.
Reference
References
Tsiantou V, Zavras D, Kousoulakou H, Geitona M, Kyriopoulos J. Generic medicines: Greek physicians' perceptions and pre-scribing policies. J Clin Pharm Ther 2009; 34(5): 547–54.
Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, et al. Use of Generics: A Critical Cost Containment Measure for All Healthcare Professionals in Europe? Pharmaceuticals (Basel) 2010; 3(8): 2470–94.
Dunne SS, Dunne CP. What do people really think of generic medicines?, A systematic review and critical appraisal of litera-ture on stakeholder perceptions of generic drugs. BMC Med 2015; 13: 173.
Hamann J, Mendel R, Kissling W, Leucht S. Psychiatrists' decision making between branded and generic drugs. Eur Neuropsychopharmacol 2013; 23(7): 686–90.
Karampli E, Souliotis K, Polyzos N, Kyriopoulos J, Chatzaki E. Pharmaceutical innovation: Impact on expenditure and out-comes and subsequent challenges for pharmaceutical policy, with a special reference to Greece. Hippokratia 2014; 18(2): 100–6.
Leopold C, Mantel-Teeuwisse AK, Vogler S, Valkova S, de Joncheere K, Leufkens HG, et al. Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. Bull World Health Organ 2014; 92(9): 630–640D.
Papaioannidou P, Ntaralas A. Attitudes in Antidepressants Use in Greece. Pharmacoepidemiol Drug Saf 2014; 23(S1): 115–6.
Papaioannidou P, Ntaralas A. Generic Use In Statin Sales In The Community of Thessaloniki, Greece. Clin Ther 2015; 37(8S): e148 ̶ 9.
World Health Organization. Guidelines for ATC classification and DDD assignment. 2015. [cited 2015 Sep 8]. Available from: http://www.whocc.no/atc_ddd_publications/guidelines/
NICE CG 178. Psychosis and schizophrenia in adults: Treat-ment and management. 2014. [cited 2015 Sep 8]. Available from: https://www.nice.org.uk/guidance/cg178/ re-sources/guidance-psychosis-and-schizophrenia-in-adults-treatment-and-management-pdf
Leiderman EA, Lorenzo L. Prescription patterns in the treat-ment of schizophrenia. Vertex 2015; 26(119): 11 ̶ 6. (Spanish)
Leopold C, Zhang F, Mantel-Teeuwisse AK, Vogler S, Valkova S, Ross-Degnan D, et al. Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: Interrupted time series analyses. Int J Equity Health 2014; 13: 53.
Jarema M, Meder J, Araszkiewicz A, Tyszkowska M. Antipsychotics in clinical practice. Treatment of the first schizophrenic episode. Psychiatr Pol 2008; 42: 841 ̶ 58. (Polish)
Meder J, Tyszkowska M, Jarema M, Araszkiewicz A, Szafrański T. Antipsychotics in clinical practice. The refractory schizophren-ic patients treatment. Psychiatr Pol 2008; 42(6): 859–73. (Polish)
Apiquian R, Fresán A, de la Fuente-Sandoval C, Ulloa RE, Nicolini H. Survey on schizophrenia treatment in Mexico: Perception and antipsychotic prescription patterns. BMC Psy-chiatry 2004; 4: 12.
Papaioannidou P, Ntaralas A. Generic use in antidepressant sales in Greece. J Bas Clin Pharmacol Toxicol 2014; 115(S1): 70.
Desmarais JE, Beauclair L, Margolese HC. Switching from brand-name to generic psychotropic medications: a literature review. CNS Neurosci Ther 2011; 17(6): 750–60.
Papaioannidou P, Kasviki P, Moschopoulos NP, Nimatoudis I. Anti-psychotic Prescribing in a Tertiary Hospital Under the Finan-cial Crisis in Greece. Pharmacoepidemiol Drug Saf 2016; 25(S3): 668.
Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. South Med Rev 2011; 4(2): 69–79.
Papaioannidou P, Kasviki P. Utilization of Antipsychotics in Eastern Thessaloniki and Kalamaria. Rev Clin Pharmacol Pharmacikinetics 2015; 29: 119–23.
Papaioannidou P, Michailidou M, Ntaralas A. Attitudes in statins use in Greece. Pharmacoepidemiol Drug Saf 2015; 24(S1): 144.
Papaioannidou P, Michailidou M, Ntaralas A, Michailidou S. Use of Antidepressants Under the Financial Crisis in Greece. Phar-macoepidemiol Drug Saf 2016; 25(S3): 665–6.